SCHEMBL5523102

SCHEMBL5523102

Cc1cc(N2CCN(C(=O)OC(C)(C)C)CC2)c2ccccc2n1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NCF1 P14598 7/20 0.72
MEN1 O00255 2/20 0.65
KMT2A Q03164 2/20 0.65
ADRB2 P07550 1/20 0.56
ADRB1 P08588 1/20 0.56
GBA1 P04062 2/20 0.56
LMNA P02545 3/20 0.56
HTT P42858 3/20 0.56
USP2 O75604 2/20 0.56
MAPK1 P28482 2/20 0.56
PKM P14618 1/20 0.56
HSD17B10 Q99714 1/20 0.56
CKS1B P61024 2/20 0.55
SKP1 P63208 2/20 0.55
SKP2 Q13309 2/20 0.55
MAPT P10636 1/20 0.54
ADAM17 P78536 1/20 0.52
SMN1; SMN2 Q16637 2/20 0.51
NPSR1 Q6W5P4 2/20 0.51
TSHR P16473 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15277916 0.88 NCF1 (0.75) NCF1MEN1KMT2AADRB2ADRB1
SCHEMBL430227 0.86 CYP2C9 (0.52) NCF1MEN1KMT2AGBA1CKS1B
SCHEMBL5761273 0.86 NCF1 (0.53) NCF1MEN1KMT2AGBA1LMNA
SCHEMBL23362072 0.85 NCF1 (0.56) NCF1MEN1KMT2AADRB2ADRB1
SCHEMBL31078190 0.85 NCF1 (0.56) NCF1MEN1KMT2AADRB2ADRB1
SCHEMBL23362298 0.85 NCF1 (0.56) NCF1MEN1KMT2AADRB2ADRB1
SCHEMBL23362074 0.85 NCF1 (0.56) NCF1MEN1KMT2AADRB2ADRB1
SCHEMBL5759182 0.85 NCF1 (0.52) NCF1MEN1KMT2AGBA1LMNA
SCHEMBL7474699 0.85 NCF1 (0.52) NCF1MEN1KMT2AGBA1CKS1B
SCHEMBL900155 0.85 NCF1 (0.82) NCF1MEN1KMT2AADRB2ADRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021123291-A1 OGA INHIBITOR COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2021-06-24 WO disclosed
EP-2621923-B1 N-HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT FOR THE TREATMENT OF PARASITIC DISEASES INTERVET INT BV (NL) 2017-03-29 EP disclosed
US-8883791-B2 N-heteroaryl compounds with cyclic bridging unit for the treatment of parasitic diseases INTERVET INC. (US) 2014-11-11 US disclosed
US-20130203768-A1 N-HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT FOR THE TREATMENT OF PARASITIC DISEASES INTERVET INC. 2013-08-08 US disclosed
US-20070197509-A1 Compositions and methods for modulating gated ion channels PAINCEPTOR PHARMA CORPORATION (CA) 2007-08-23 US disclosed
US-20070197509-A1 Compositions and methods for modulating gated ion channels PAINCEPTOR PHARMA CORPORATION (CA) 2007-08-23 US disclosed
US-20070197509-A1 Compositions and methods for modulating gated ion channels PAINCEPTOR PHARMA CORPORATION (CA) 2007-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130203768-A1 N-HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT FOR THE TREATMENT OF PARASITIC DISEASES PIGO, HNMT, PIGS NCF1 823/4885MEN1 1483/4885KMT2A 2910/4885
US-20070197509-A1 Compositions and methods for modulating gated ion channels KCNN3, KCNN2, HCN3 NCF1 2805/4885MEN1 4412/4885KMT2A 2807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.